Zargis Medical, a subsidiary of Speedus, has reported that Australia's Therapeutic Goods Administration, the Australian equivalent of the FDA, has cleared the StethAssist and Cardioscan devices for sale in Australia.
The clearance allows Zargis to immediately begin marketing of StethAssist, Cardioscan and the compatible stethoscope in all Australian states and territories.
StethAssist allows healthcare professionals to record and visualize heart, lung and other body sounds and share the findings via internet with the colleagues. The Cardioscan heart sound analysis software is designed to help physicians analyze cardiac sounds for the identification and classification of suspected heart murmurs, which can be signs of heart disease. Both devices connect wirelessly to a Bluetooth-enabled digital stethoscope for the recording and playback of sounds.
The introduction of these devices into Australia will provide benefits during face-to-face patient encounters and allow healthcare providers to extend the use of auscultation (listening with a stethoscope) through the internet to situations and environments where face-to-face encounters are not practical.
Zargis is a global medical device company focused on improving health outcomes and cost-effectiveness through diagnostic support software and innovation. Zargis is majority-owned by Speedus and both 3M Company and Siemens Corporate Research, a division of Siemens AG, hold equity positions.